NO20075648L - Vaksinesammensetning - Google Patents

Vaksinesammensetning

Info

Publication number
NO20075648L
NO20075648L NO20075648A NO20075648A NO20075648L NO 20075648 L NO20075648 L NO 20075648L NO 20075648 A NO20075648 A NO 20075648A NO 20075648 A NO20075648 A NO 20075648A NO 20075648 L NO20075648 L NO 20075648L
Authority
NO
Norway
Prior art keywords
vectors
adenoviruses
hiv
relates
methods
Prior art date
Application number
NO20075648A
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Cathrine Ann Van Wely
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075648(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20075648L publication Critical patent/NO20075648L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse angår virusvektorer omfattende oligonukleotider som koder for HIV-polypeptider, mer spesielt hvor virus-vektoren er et adenovirus. Spesielt er slike adenovirus ikke-humane primat-adenovirus så som simian-adenovirus, mer spesielt sjimpanse-adenovirus. Spesielt angår oppfinnelsen adenovirus-vektorer som omfatter HIV- polynukleotidsekvenser som koder for multiple forskjellige HIV-antigener, for eksempel to eller tre eller flere HIV-antigener. Oppfinnelsen angår videre metoder for fremstilling av virus-vektorer, virus-vektorer produsert ved metodene og anvendelse av vektorene i medisin, spesielt profylaktisk eller terapeutisk vaksinasjon.
NO20075648A 2005-05-12 2007-11-06 Vaksinesammensetning NO20075648L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12
PCT/EP2006/004854 WO2006120034A1 (en) 2005-05-12 2006-05-10 Vaccine composition

Publications (1)

Publication Number Publication Date
NO20075648L true NO20075648L (no) 2008-02-07

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075648A NO20075648L (no) 2005-05-12 2007-11-06 Vaksinesammensetning

Country Status (20)

Country Link
US (1) US20090208515A1 (no)
EP (1) EP1880012B1 (no)
JP (2) JP5175178B2 (no)
KR (1) KR101451620B1 (no)
CN (2) CN101384722A (no)
AR (1) AR053275A1 (no)
AU (1) AU2006245920A1 (no)
BR (1) BRPI0608798A2 (no)
CA (1) CA2608316A1 (no)
EA (1) EA200702190A1 (no)
ES (1) ES2546330T3 (no)
IL (1) IL186828A (no)
MA (1) MA29458B1 (no)
MX (1) MX2007014038A (no)
NO (1) NO20075648L (no)
PE (1) PE20061372A1 (no)
SG (1) SG182173A1 (no)
TW (1) TW200716750A (no)
WO (1) WO2006120034A1 (no)
ZA (1) ZA200709518B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
DK2220241T3 (en) 2007-11-28 2017-01-09 Univ Pennsylvania Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
HUE031636T2 (en) 2007-11-28 2017-07-28 Univ Pennsylvania SAdV-28,27, -29, -32, -33, and -34 simian B subgenus adenoviruses
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
DK2694101T3 (en) 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
JP2016513666A (ja) * 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 組織メタロプロテイナーゼ阻害物質３型（ｔｉｍｐ−３）の変異体、組成物、及び方法
JP6887955B2 (ja) 2015-03-18 2021-06-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 組換え体発現系のアッセイ
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
CN108025058B (zh) * 2015-06-12 2022-12-16 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
WO2017011336A1 (en) 2015-07-10 2017-01-19 E.&J. Gallo Winery System and method for dispensing a beverage
KR102573534B1 (ko) 2016-05-12 2023-08-31 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
EP3490610A4 (en) 2016-08-01 2020-05-20 The Wistar Institute Of Anatomy And Biology DEFICIENTLY REPLICABLE ADENOVIRAL VECTOR COMPOSITIONS AND METHODS FOR VACCINE APPLICATIONS
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
KR20040043129A (ko) * 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
US20070015721A1 (en) * 2001-09-20 2007-01-18 Andrew Beaton Hiv-gag codon-optimised dna vaccines
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
WO2005030964A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
MA29458B1 (fr) 2008-05-02
JP5175178B2 (ja) 2013-04-03
CA2608316A1 (en) 2006-11-16
ZA200709518B (en) 2014-01-29
BRPI0608798A2 (pt) 2011-03-15
SG182173A1 (en) 2012-07-30
PE20061372A1 (es) 2007-01-16
KR101451620B1 (ko) 2014-10-21
EP1880012B1 (en) 2015-07-08
MX2007014038A (es) 2008-02-11
IL186828A0 (en) 2008-02-09
JP2008539746A (ja) 2008-11-20
CN101384722A (zh) 2009-03-11
TW200716750A (en) 2007-05-01
CN103088060A (zh) 2013-05-08
AU2006245920A1 (en) 2006-11-16
WO2006120034A8 (en) 2007-11-15
KR20080021659A (ko) 2008-03-07
EP1880012A1 (en) 2008-01-23
AR053275A1 (es) 2007-04-25
IL186828A (en) 2015-06-30
JP2013046613A (ja) 2013-03-07
WO2006120034A1 (en) 2006-11-16
EA200702190A1 (ru) 2008-04-28
US20090208515A1 (en) 2009-08-20
ES2546330T3 (es) 2015-09-22

Similar Documents

Publication Publication Date Title
NO20075648L (no) Vaksinesammensetning
NO20090194L (no) Rekombinant viral vaksine
Capone et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques
Forrester et al. Recombination in rabbit haemorrhagic disease virus: possible impact on evolution and epidemiology
WO2008014521A8 (en) Improved vaccines and methods for using the same
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
JP2009544333A5 (no)
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007015783A3 (en) Attenuated strains of flaviviruses , and uses thereof
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
WO2003076591A3 (en) Compositions and methods for generating an immune response
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
PH12021550785A1 (en) Virus vaccine
Yu et al. Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan
WO2008127307A3 (en) Induction of an immune response against dengue virus using prime-boost approach
WO2007143606A3 (en) Hiv-1 clade a consensus sequences, antigens, and transgenes
WO2010135054A3 (en) Mutations in a toll-like receptor motif in the ns4b of classical swine fever virus skin brescia influences virulence in swine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application